瘦素与抗精神病药所致体重增加

抗精神病药所致体重增加是其主要不良反应之一．已越来越受到重视，这不仅影响患者的依从性，还会引发与肥胖有关的疾病，如糖尿病、高血压、冠心病等。近年来对瘦素与抗精神病药所致体重增加之间的关系进行研究。     

抗精神病药所致体重增加

抗精神病药治疗期间出现体重增加相当常见，研究发现，致体重增加作用最为明显的是氯氮平及奥兰扎平，甲硫达嗪，色汀度，氯丙嗪次之，利培酮又次之，氟哌啶醇及氟奋乃静等则相对较轻，因治疗期间体重增加直接影响患对治疗的依从性，所以应引起足够的重视。     

抗精神病药物治疗所致患者体重增加及其相关因素初探

目的 探讨抗精神病药（APD）引起患者体重增加及其相关因素。方法 对67例首次住院单用APD治疗的精神分裂症患者进行住院及出院后4个月的随访评估。结果 各时点体重增加与GI评分无相关性，体重增加在出院时与BPRS、SAPS减分值有相关性，而随访期与SANS减分值有相关意义。逐步回归分析显示，在α＝0.05水平上，进入回归方程的因素依次为：APD品种，最大服药剂量与服药时间的积、阴性症状，病前1年最佳功能水平。结论 APD治疗中的体重增加，是与疗效无关的药物副作用及其形成受药物、精神症状及综合社会心理因素等方面的影响，而饮食与活动的中介作用不应低估。控制体重增加有重要的医学社会意义。     

抗精神病药所致体重增加

抗精神病药治疗期间出现体重增加者相当常见。研究发现 ,致体重增加作用最为明显的是氯氮平及奥兰扎平 ,甲硫达嗪、色汀度、氯丙嗪次之 ,利培酮又次之 ,氟哌啶醇及氟奋乃静等则相对较轻。因治疗期间体重增加直接影响患者对治疗的依从性 ,所以应引起足够的重视。     

运动疗法对抗精神病药所致体重增加的影响

抗精神病药所致体重增加已日益受到关注，本研究尝试着探讨运动训练对抗精神病药所致体重增加的影响。     

抗精神病药对血清细胞因子的影响

目的：探讨抗精神病药对精神分裂症患者血清细胞因子的影响。方法：对４６例精神分裂症患者给予抗精神病药治疗６周,在治疗前后检测血清ＩＬ－６和ＴＮＦ－α水平,并采用阳性与阴性症状量表（ＰＡＮＳＳ）、副反应量表（ＴＥＳＳ）评估临床症状变化及药物副反应。结果：抗精神病药治疗后,血清ＩＬ－６水平显著下降,血清ＴＮＦ－α水平变化不显著。治疗前血清ＩＬ－６水平与ＰＡＮＳＳ阳性因子分显血清ＩＬ－６水平显著下降,血清     

抗精神病药物所致体重增加的护理干预

目的 为研究抗精神病药物所致体重增加的护理干预效果。方法 将83例抗精神病药物随机分为两组，干预组（n=42例）和未干预组（n=41例），对干预组实施护理干预。结果 未干预组体重增加差异显著高于干预组（P〈0．05）。结论 护理干预对抗精神病药物所致体重增加的疗效较好。     

抗精神病药物所致体重增加的药物遗传学研究

本文总结了抗精神病药源性体重增加的药物反应遗传学的研究现状，分析了研究中存在的不足并做一展望。     

抗精神病药物所致体重增加的药物遗传学研究

本文总结了抗精神病药源性体重增加的药物反应遗传学的研究现状 ,分析了研究中存在的不足并做一展望     

与抗精神病药相关的体重增加

本文对与抗精神病药有关的体重增加从临床特征，药物间差异，可能的机制与处理等方面作一综述。     

Antipsychotic-induced weight gain: a comprehensive research synthesis.

OBJECTIVE: The purpose of this study was to estimate and compare the effects of antipsychotics-both the newer ones and the conventional ones-on body weight. Method: A comprehensive literature search identified 81 English- and non-English-language articles that included data on weight change in antipsychotic-treated patients. For each agent, a meta-analysis and random effects metaregression estimated the weight change after 10 weeks of treatment at a standard dose. A comprehensive narrative review was also conducted on all articles that did not yield quantitative information but did yield important qualitative information. RESULTS: Placebo was associated with a mean weight reduction of 0.74 kg. Among conventional agents, mean weight change ranged from a reduction of 0.39 kg with molindone to an increase of 3.19 kg with thioridazine. Among newer antipsychotic agents, mean increases were as follows: clozapine, 4.45 kg; olanzapine, 4.15 kg; sertindole, 2.92 kg; risperidone, 2.10 kg; and ziprasidone, 0.04 kg. Insufficient data were available to evaluate quetiapine at 10 weeks. CONCLUSIONS: Both conventional and newer antipsychotics are associated with weight gain. Among the newer agents, clozapine appears to have the greatest potential to induce weight gain, and ziprasidone the least. The differences among newer agents may affect compliance with medication and health risk.     

Management of weight gain in patients with schizophrenia

Of the roughly 55% of the United States population that is considered overweight, half meet the criteria for obesity. Obesity is associated with serious health risks, but many clinicians graduate from medical school without a clear understanding of the effects of the foods that they and their patients consume. Obesity is more prevalent in people with mental illnesses, which poses an even greater challenge to clinicians. Antipsychotic treatment can cause weight gain, and mentally ill patients generally lack an understanding of nutrition as well as the ability to afford healthier foods. Therefore, clinicians must educate themselves about appropriate measures for preventing weight gain before or immediately after initiating antipsychotic therapy. Strategies for weight gain management that have proven effective in clinical trials include regular check-ups, lifestyle and medication counseling, medication assessments, behavioral control programs, and pharmacologic intervention. These approaches are necessary for clinicians to consider if efforts at reintegration of mentally ill patients are to succeed.     

Antipsychotic-induced weight gain--pharmacogenetic studies

Drug-naive patients with schizophrenia often present metabolic abnormalities and obesity. Weight gain may be the side effect of treatment with many antipsychotic drugs. Genetic effects, besides many other factors, are known to influence obesity in patients with schizophrenia treated with antipsychotics. Numerous studies of several genes' polymorphisms have been performed. -759C/T polymorphism of 5HT2C gene attracted most attention. In 5 independent studies of this polymorphism the association between T allele with the lower AP-induced weight gain was detected. No associations could be detected between weight gain and other polymorphisms of serotonergic system genes as well as histaminergic system genes. Studies of adrenergic and dopaminergic system have neither produced any unambiguous results. Analysis of the newest candidate genes (SAP-25, leptin gene) confirmed the role of genetic factors in AP-induced weight gain. It is worth emphasising, that the studies have been conducted in relatively small and heterogenic groups and that various treatment strategies were used.